Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
Purpose: There is evidence that adding cetuximab can overcome resistance to irinotecan, but a similar analysis with Panitumumab isn't readily available. This study evaluated the activity of each anti-EGFR plus irinotecan as a salvage third-line treatment for metastatic colorectal cancer. Method...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S246829422500005X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823864256803635200 |
|---|---|
| author | Maria Ignez Freitas Melro Braghiroli Daniel Santos Rocha Sobral Filho Juliana Goes Martins Fagundes Elizabeth Zambrano Mendoza Maria Fernanda Batistuzzo Vicentini Neffa Karla Souza Campos Leonardo Gomes da Fonseca Renata Colombo Bonadio Aley Talans Oddone Freitas Melro Braghiroli Maria Cecília Mathias-Machado Jorge Sabbaga Camila Motta Venchiarutti Moniz Paulo Marcelo Gehm Hoff |
| author_facet | Maria Ignez Freitas Melro Braghiroli Daniel Santos Rocha Sobral Filho Juliana Goes Martins Fagundes Elizabeth Zambrano Mendoza Maria Fernanda Batistuzzo Vicentini Neffa Karla Souza Campos Leonardo Gomes da Fonseca Renata Colombo Bonadio Aley Talans Oddone Freitas Melro Braghiroli Maria Cecília Mathias-Machado Jorge Sabbaga Camila Motta Venchiarutti Moniz Paulo Marcelo Gehm Hoff |
| author_sort | Maria Ignez Freitas Melro Braghiroli |
| collection | DOAJ |
| description | Purpose: There is evidence that adding cetuximab can overcome resistance to irinotecan, but a similar analysis with Panitumumab isn't readily available. This study evaluated the activity of each anti-EGFR plus irinotecan as a salvage third-line treatment for metastatic colorectal cancer. Methods: This is a retrospective cohort of metastatic colorectal cancer patients who progressed to irinotecan monotherapy and were exposed to an anti-EGFR antibody as a third line of treatment. This study was conducted at a single cancer center in Brazil. The primary outcome was overall survival. The secondary outcomes were objective response rate, stratified by primary tumor sidedness, progression-free survival, and toxicity. Results: This analysis included 412 patients who had progressed on irinotecan and were KRAS wild-type. One hundred eighty-two received Irinotecan plus Cetuximab (I + C group) and 230 Irinotecan plus Panitumumab (I + P group). There was no significant difference in median overall survival between treatment groups (9.1 months [I + C] vs 10.1 months [I + P]; p = 0.76). There was also no difference in progression-free survival (3.63 months [I + C] vs 3.73 months [I + P]; p = 0.19) and objective response rate (23.0 % [I + C] vs 22.3 % [I + P]; p = 0.97). Patients with right-sided tumors had worse overall survival than left-sided (6.2 months vs 10.1 months; p = 0.003) but presented a better objective response rate with panitumumab (8.3 % [I + P] vs 3.3 % [I + C]). There were more infusion reactions with cetuximab. Conclusions: Panitumumab and cetuximab have similar activity when combined with irinotecan as treatment for patients with disease progression with an irinotecan regimen, potentially rescuing the irinotecan activity. |
| format | Article |
| id | doaj-art-936e51c2ab6d49b19c168587e2169c02 |
| institution | Kabale University |
| issn | 2468-2942 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj-art-936e51c2ab6d49b19c168587e2169c022025-02-09T05:00:47ZengElsevierCancer Treatment and Research Communications2468-29422024-01-0142100867Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancerMaria Ignez Freitas Melro Braghiroli0Daniel Santos Rocha Sobral Filho1Juliana Goes Martins Fagundes2Elizabeth Zambrano Mendoza3Maria Fernanda Batistuzzo Vicentini Neffa4Karla Souza Campos5Leonardo Gomes da Fonseca6Renata Colombo Bonadio7Aley Talans8Oddone Freitas Melro Braghiroli9Maria Cecília Mathias-Machado10Jorge Sabbaga11Camila Motta Venchiarutti Moniz12Paulo Marcelo Gehm Hoff13Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo (SP), 02146-000, Brazil; Instituto D´Or de Pesquisa e Ensino, Av. Brigadeiro Luis Antonio, 5001, Jardim Paulista, São Paulo (SP), 01401-002, BrazilInstituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo (SP), 02146-000, Brazil; Corresponding author at: Av Dr Arnaldo 251, Cerqueira Cesar São Paulo (SP) Brazil.Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo (SP), 02146-000, BrazilInstituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo (SP), 02146-000, BrazilInstituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo (SP), 02146-000, BrazilInstituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo (SP), 02146-000, BrazilInstituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo (SP), 02146-000, Brazil; Instituto D´Or de Pesquisa e Ensino, Av. Brigadeiro Luis Antonio, 5001, Jardim Paulista, São Paulo (SP), 01401-002, BrazilInstituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo (SP), 02146-000, Brazil; Instituto D´Or de Pesquisa e Ensino, Av. Brigadeiro Luis Antonio, 5001, Jardim Paulista, São Paulo (SP), 01401-002, BrazilInstituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo (SP), 02146-000, BrazilInstituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo (SP), 02146-000, Brazil; Instituto D´Or de Pesquisa e Ensino, Av. Brigadeiro Luis Antonio, 5001, Jardim Paulista, São Paulo (SP), 01401-002, BrazilInstituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo (SP), 02146-000, BrazilInstituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo (SP), 02146-000, Brazil; Instituto D´Or de Pesquisa e Ensino, Av. Brigadeiro Luis Antonio, 5001, Jardim Paulista, São Paulo (SP), 01401-002, BrazilInstituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo (SP), 02146-000, Brazil; Instituto D´Or de Pesquisa e Ensino, Av. Brigadeiro Luis Antonio, 5001, Jardim Paulista, São Paulo (SP), 01401-002, BrazilInstituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Av. Dr. Arnaldo, 251, Cerqueira César, São Paulo (SP), 02146-000, Brazil; Instituto D´Or de Pesquisa e Ensino, Av. Brigadeiro Luis Antonio, 5001, Jardim Paulista, São Paulo (SP), 01401-002, BrazilPurpose: There is evidence that adding cetuximab can overcome resistance to irinotecan, but a similar analysis with Panitumumab isn't readily available. This study evaluated the activity of each anti-EGFR plus irinotecan as a salvage third-line treatment for metastatic colorectal cancer. Methods: This is a retrospective cohort of metastatic colorectal cancer patients who progressed to irinotecan monotherapy and were exposed to an anti-EGFR antibody as a third line of treatment. This study was conducted at a single cancer center in Brazil. The primary outcome was overall survival. The secondary outcomes were objective response rate, stratified by primary tumor sidedness, progression-free survival, and toxicity. Results: This analysis included 412 patients who had progressed on irinotecan and were KRAS wild-type. One hundred eighty-two received Irinotecan plus Cetuximab (I + C group) and 230 Irinotecan plus Panitumumab (I + P group). There was no significant difference in median overall survival between treatment groups (9.1 months [I + C] vs 10.1 months [I + P]; p = 0.76). There was also no difference in progression-free survival (3.63 months [I + C] vs 3.73 months [I + P]; p = 0.19) and objective response rate (23.0 % [I + C] vs 22.3 % [I + P]; p = 0.97). Patients with right-sided tumors had worse overall survival than left-sided (6.2 months vs 10.1 months; p = 0.003) but presented a better objective response rate with panitumumab (8.3 % [I + P] vs 3.3 % [I + C]). There were more infusion reactions with cetuximab. Conclusions: Panitumumab and cetuximab have similar activity when combined with irinotecan as treatment for patients with disease progression with an irinotecan regimen, potentially rescuing the irinotecan activity.http://www.sciencedirect.com/science/article/pii/S246829422500005XColorectal cancerPanitumumabCetuximabThird-lineRefractoriness |
| spellingShingle | Maria Ignez Freitas Melro Braghiroli Daniel Santos Rocha Sobral Filho Juliana Goes Martins Fagundes Elizabeth Zambrano Mendoza Maria Fernanda Batistuzzo Vicentini Neffa Karla Souza Campos Leonardo Gomes da Fonseca Renata Colombo Bonadio Aley Talans Oddone Freitas Melro Braghiroli Maria Cecília Mathias-Machado Jorge Sabbaga Camila Motta Venchiarutti Moniz Paulo Marcelo Gehm Hoff Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer Cancer Treatment and Research Communications Colorectal cancer Panitumumab Cetuximab Third-line Refractoriness |
| title | Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer |
| title_full | Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer |
| title_fullStr | Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer |
| title_full_unstemmed | Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer |
| title_short | Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer |
| title_sort | panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer |
| topic | Colorectal cancer Panitumumab Cetuximab Third-line Refractoriness |
| url | http://www.sciencedirect.com/science/article/pii/S246829422500005X |
| work_keys_str_mv | AT mariaignezfreitasmelrobraghiroli panitumumabversuscetuximabincombinationwithirinotecaninrefractorymetastaticcolorectalcancer AT danielsantosrochasobralfilho panitumumabversuscetuximabincombinationwithirinotecaninrefractorymetastaticcolorectalcancer AT julianagoesmartinsfagundes panitumumabversuscetuximabincombinationwithirinotecaninrefractorymetastaticcolorectalcancer AT elizabethzambranomendoza panitumumabversuscetuximabincombinationwithirinotecaninrefractorymetastaticcolorectalcancer AT mariafernandabatistuzzovicentinineffa panitumumabversuscetuximabincombinationwithirinotecaninrefractorymetastaticcolorectalcancer AT karlasouzacampos panitumumabversuscetuximabincombinationwithirinotecaninrefractorymetastaticcolorectalcancer AT leonardogomesdafonseca panitumumabversuscetuximabincombinationwithirinotecaninrefractorymetastaticcolorectalcancer AT renatacolombobonadio panitumumabversuscetuximabincombinationwithirinotecaninrefractorymetastaticcolorectalcancer AT aleytalans panitumumabversuscetuximabincombinationwithirinotecaninrefractorymetastaticcolorectalcancer AT oddonefreitasmelrobraghiroli panitumumabversuscetuximabincombinationwithirinotecaninrefractorymetastaticcolorectalcancer AT mariaceciliamathiasmachado panitumumabversuscetuximabincombinationwithirinotecaninrefractorymetastaticcolorectalcancer AT jorgesabbaga panitumumabversuscetuximabincombinationwithirinotecaninrefractorymetastaticcolorectalcancer AT camilamottavenchiaruttimoniz panitumumabversuscetuximabincombinationwithirinotecaninrefractorymetastaticcolorectalcancer AT paulomarcelogehmhoff panitumumabversuscetuximabincombinationwithirinotecaninrefractorymetastaticcolorectalcancer |